Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)

ALPS is a disorder of apoptosis resulting in accumulation of autoreactive lymphocytes, leading to marked lymphadenopathy, hepatosplenomegaly, and multilineage cytopenias due to splenic sequestration and/or autoimmune destruction often presenting in childhood. We summarize our experience of rituximab use during the last 8 years in 12 patients, 9 children, and 3 adults, out of 259 individuals with ALPS, belonging to 166 families currently enrolled in studies at the National Institutes of Health.

[1]  V Koneti Rao,et al.  Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS). , 2009, Experimental hematology.

[2]  M. Loh,et al.  One year follow‐up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab , 2009, Pediatric blood & cancer.

[3]  C. Galambos.  Common variable immunodeficiency disorders: division into distinct clinical phenotypes , 2009 .

[4]  D. Fulcher,et al.  B‐cell maturation defects in common variable immunodeficiency and association with clinical features , 2008, Pathology.

[5]  D. Teachey,et al.  Targeting Notch signaling in autoimmune and lymphoproliferative disease. , 2008, Blood.

[6]  St Michael’s.  Rituximab in the treatment of autoimmune haematological disorders , 2008 .

[7]  J. Puck,et al.  Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr−/− mice or in patients with autoimmune lymphoproliferative syndrome , 2007, American journal of hematology.

[8]  V. Hoffmann,et al.  Hydroxychloroquine Diminishes Lymphoproliferation in the Fas Deficient MRL/lpr−/− Murine Model of Autoimmune Lymphoproliferative Syndrome (ALPS). , 2007 .

[9]  A. Wei,et al.  Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7+2 T>C) affecting the Fas gene , 2007, European journal of haematology.

[10]  I. Sanz,et al.  Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. , 2007, Arthritis and rheumatism.

[11]  J. Puck,et al.  Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib , 2007, BMC Medical Genetics.

[12]  Peter J. Munson,et al.  NRAS mutation causes a human autoimmune lymphoproliferative syndrome , 2007, Proceedings of the National Academy of Sciences.

[13]  T. Koike,et al.  Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non‐Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation , 2007, British journal of haematology.

[14]  E. Neufeld,et al.  Treatment with rituximab in benign and malignant hematologic disorders in children. , 2007, The Journal of pediatrics.

[15]  Jb Oliveira,et al.  NRAS mutation causes a human autoimmune lymphopro-liferative disease , 2007 .

[16]  J. Stockman.  Prospective Phase 1/2 Study of Rituximab in Childhood and Adolescent Chronic Immune Thrombocytopenic Purpura , 2007 .

[17]  F. Rieux-Laucat,et al.  Mycophenolate mofetil as an alternate immunosuppressor for autoimmune lymphoproliferative syndrome. , 2006, Journal of pediatric hematology/oncology.

[18]  K. Sullivan,et al.  Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). , 2006, Blood.

[19]  A. Schäffer,et al.  Genetic alterations in caspase-10 may be causative or protective in autoimmune lymphoproliferative syndrome , 2006, Human Genetics.

[20]  J. Puck,et al.  Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome , 2005, British journal of haematology.

[21]  J. B. Oliveira,et al.  Autoimmune lymphoproliferative syndrome , 2004, Current opinion in allergy and clinical immunology.

[22]  F. Rieux-Laucat,et al.  Autoimmune lymphoproliferative syndrome with somatic Fas mutations. , 2004, The New England journal of medicine.

[23]  W. Abdullah.  Pediatr Blood Cancer , 2004 .

[24]  S. Perrotta,et al.  Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. , 2003, Blood.

[25]  J. Puck,et al.  Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency , 2002, Nature.

[26]  A. Mehta,et al.  Effect of anti‐CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome , 2002, British journal of haematology.

[27]  R. Beyaert,et al.  Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations , 2002, British journal of haematology.

[28]  J. Puck,et al.  Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. , 2001, Blood.

[29]  S. Amadori,et al.  Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. , 2001, Blood.

[30]  A. Marx,et al.  The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. , 2001, Blood.

[31]  K. Thielemans,et al.  Autoimmune Lymphoproliferative Syndrome Type III: An Indefinite Disorder , 2001, Leukemia & lymphoma.

[32]  J. Puck,et al.  An Inherited Disorder of Lymphocyte Apoptosis: The Autoimmune Lymphoproliferative Syndrome , 1999, Annals of Internal Medicine.

[33]  J. Puck,et al.  Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. , 1999, American journal of human genetics.

[34]  E. Jaffe,et al.  Pathological findings in human autoimmune lymphoproliferative syndrome. , 1998, The American journal of pathology.

[35]  E. Jaffe,et al.  Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. , 1997, Blood.

[36]  Warren Strober,et al.  Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome , 1995, Cell.

[37]  F. Rieux-Laucat,et al.  Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. , 1995, Science.

[38]  E. Jaffe,et al.  A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. , 1992, The Journal of clinical investigation.

[39]  C. Smith,et al.  Chronic lymphadenopathy simulating malignant lymphoma. , 1966, The Journal of pediatrics.